ArticleJCI insight2016
Low-dose IL-2 selectively activates subsets of CD4
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 135 citations in OpenAlex.
- Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.Annals of hematology · 2021Trial
- Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.Blood advances · 2019Trial
- Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.Blood advances · 2019Trial
- Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Phenotypic Analysis of Human Lymph Nodes in Subjects With New-Onset Type 1 Diabetes and Healthy Individuals by Flow Cytometry.Frontiers in immunology · 2019Trial
- Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Programmed death-ligand 1 on ex vivo-expanded toll-like-receptor-Bregs prevents allograft rejection by Breg viability promotion, CD4American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Advances in Cell Therapy for Chronic Graft-versus-Host Disease: Prophylactic and Therapeutic Perspectives.Clinical and experimental medicine · 2026Review
- Review
- Serum IL-2 levels are associated with disease activity and related to dyslipidaemia and the immunological profile in systemic lupus erythematosus.Lupus science & medicine · 2026Article
- Decoding Treg diversity and dysfunction to advance Treg-based therapies in autoimmune and inflammatory diseases.Frontiers in immunology · 2026Review
- Suxiao Jiuxin Pill Promotes Post-Myocardial Infarction Cardiac Repair by Enhancing Regulatory T Cell Function via the ST2L Signaling Pathway.Journal of inflammation research · 2026Article
- Case Report: IL2RA (CD25) deficiency: first reported cases in Morocco.Frontiers in immunology · 2026Article
- Generating tolerance through in situ recruitment of regulatory T cells for allogeneic cell transplantation in a bioengineered lymphoid platform.Materials today. Bio · 2025Article
- Targeted regulatory T cell activation by site-specific PEGylated interleukin-2 mitigates autoimmune inflammation.Journal of translational autoimmunity · 2025Article
- Multi-omics identification of activated T cells and spatial PD-1/PD-L1 signaling as biomarkers of diabetic foot ulcer healing.bioRxiv : the preprint server for biology · 2025Article
- Regulatory T cell therapy promotes TGF-β and IL-6-dependent pro-inflammatory Th17 cell generation by reducing IL-2.Nature communications · 2025Article
- CyTOF as a suitable tool for stratification and monitoring of cancer patients.Journal of translational medicine · 2025Review
- Spatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting Treg cell subset in human clear-cell renal cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.Communications medicine · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 2 countries.
Masahiro HirakawaDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Tiago R MatosDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Hongye LiuDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
John KorethDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Haesook T KimDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Nicole E PaulDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kazuyuki MuraseDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Jennifer WhangboDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Ana C AlhoDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Sarah NikiforowDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Corey CutlerDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Vincent T HoDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Philippe ArmandDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Edwin P AlyeaDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Joseph H AntinDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Bruce R BlazarDivision of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Joao F LacerdaInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Robert J SoifferDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Jerome RitzDivision of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Harvard University · USUniversity of Lisbon · PTDana-Farber Cancer Institute · USUniversity of Minnesota · US
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5MProject 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MIN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2MManipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7MReconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5MNCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560NHLBI NIH HHS R01 HL118979NIAID NIH HHS P01 AI056299NIAID NIH HHS R01 AI034495
Abstract
CD4
Indexed as
Hematopoietic Stem Cell TransplantationAdultAgedCD56 AntigenFemaleGraft vs Host DiseaseHumansInterleukin-2Killer Cells, NaturalMaleMiddle AgedSTAT5 Transcription FactorT-Lymphocytes, RegulatoryCD56 AntigenInterleukin-2STAT5 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.